Seek Returns

BIO vs. PCVX: Bio-Rad Laboratories vs. Vaxcyte Stock Comparison

How do Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while PCVX is classified in Biotechnology.

Bio-Rad Laboratories (BIO) has more than two decades of public-market history since February 27, 1980, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
Profile ItemBIOPCVX
NameBio-Rad Laboratories Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization10.26 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateFebruary 27, 1980June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO
PCVX
GSPC
Loading price history…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
MetricBIOPCVX
Total Return (1Y)28.31%59.00%
Total Return (3Y, Annualized)8.52%11.29%
Total Return (5Y, Annualized)-11.74%21.60%

Risk Profile

Drawdown History

BIO
PCVX
GSPC
Loading price history…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
MetricBIOPCVX
Volatility (1Y, Annualized)36.50%56.01%
Beta (5Y)1.031.26
Max Drawdown (5Y)-72.24%-76.22%
Avg. Volume (3M)250.78K2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
MetricBIOPCVX
Sharpe Ratio (1Y)0.660.98
Sortino Ratio (1Y)0.981.76

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bio-Rad Laboratories (BIO) reports 14.27%, ranking against industry peers normally.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bio-Rad Laboratories (BIO) at 39.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Bio-Rad Laboratories (BIO) at 11.82% and Vaxcyte (PCVX) at 0.00% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.82%

Max
83.12%
Q3
14.77%
BIO
11.82%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
MetricBIOPCVX
ROE (TTM)14.27%-42.68%
ROA (TTM)1.50%-24.98%
Net Margin (TTM)39.45%0.00%
Operating Margin (TTM)11.82%0.00%
Gross Margin (TTM)52.19%0.00%

Growth

Revenue Growth

Only one side can be read here: Bio-Rad Laboratories (BIO) reports revenue growth of 0.65%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Bio-Rad Laboratories (BIO) nor Vaxcyte (PCVX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
MetricBIOPCVX
Revenue Growth (YoY)0.65%--
Revenue Growth (3Y CAGR)-2.68%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Bio-Rad Laboratories (BIO) at 3.18 and Vaxcyte (PCVX) at 4.56 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO
3.18
Q1
2.47
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Bio-Rad Laboratories (BIO) at 0.18 and Vaxcyte (PCVX) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO
0.18
Median
0.15
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
MetricBIOPCVX
Current Ratio (MRQ)3.184.56
Debt / Equity (MRQ)0.180.09
Net Debt / EBITDA-0.73--

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Bio-Rad Laboratories (BIO) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
MetricBIOPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Bio-Rad Laboratories (BIO) trades at 10.14 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.14

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO
10.14
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; BIO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Bio-Rad Laboratories (BIO), whose P/S ratio of 3.96 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.96

Max
58.18
Q3
25.77
Median
7.30
BIO
3.96
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; BIO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Vaxcyte (PCVX) at 3.83 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO
1.35
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO) and Vaxcyte (PCVX)
MetricBIOPCVX
P/E Ratio (TTM)10.14--
P/S Ratio (TTM)3.96--
P/B Ratio (MRQ)1.353.83
Free Cash Flow Yield (TTM)2.65%-5.24%